Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.
For this Initiative, Lilly has opened access to its greatest assets, a library of 500,000 compounds. The company also is lending its immense drug discovery expertise and organizational savvy, and is contributing the latest, most innovative technologies used in drug discovery to be applied to the search for new drugs to fight TB. The $15 million Lilly has given to support this historic undertaking is part of Lilly's $135 million commitment to control MDR-TB through The Lilly MDR-TB Partnership, which mobilizes 18 partners on five continents to stop the spread of the disease and save lives. Additional information can be found at http://www.lillymdr-tb.com.
IDRI is a Seattle-based not-for-profit organization committed to
applying innovative science to the research and development of products to
prevent, detect and treat infectious diseases of poverty. By integrating
capabilities, IDRI strives to create an efficient pathway bringing
scientific innovation from the lab to the people who need it most. For more
information, go to http://www.idri.o
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved